Log In
Print
BCIQ
Print
Print this Print this
 

MGCD290

  Manage Alerts
Collapse Summary General Information
Company Mirati Therapeutics Inc.
DescriptionSmall molecule inhibitor of the fungal histone deacetylase (HDAC) enzyme HOS2
Molecular Target Histone deacetylase (HDAC)
Mechanism of ActionHistone deacetylase (HDAC) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationFungal infection
Indication DetailsTreat acute vulvovaginal candidiasis; Treat fungal infections; Treat moderate to severe vulvovaginal candidiasis; Treat recurrent vulvovaginal candidiasis
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today